2025
Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]).
Nader Marta G, Ameye L, Viale G, Martins-Branco D, Paesmans M, Aftimos P, Desmedt C, Choudhury A, Wolff A, Krop I, Piccart-Gebhart M, de Azambuja E. Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). Journal Of Clinical Oncology 2025, 43: 542-542. DOI: 10.1200/jco.2025.43.16_suppl.542.Peer-Reviewed Original ResearchTime to distant recurrenceInvasive lobular carcinomaNo special typeDisease-free survivalCentral nervous system recurrenceCentral pathology reviewTrastuzumab-containing armsCentral nervous systemOutcomes of patientsLong-term outcomesOverall survivalHistological subtypesALTTO trialPathology reviewLobular carcinomaBreast cancerHistological subtype of breast cancerLong-term outcomes of patientsIncidence of CNS metastasesRandomized phase III trialSubtypes of breast cancerProportion of invasive lobular carcinomasLocal pathologyHormone receptor-positivePattern of relapseTP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer.
Casasanta N, Kahn A, Fischbach N, Pavlick D, Lustberg M, LoRusso P, Sokol E, Graf R, Quintanilha J, Li G, Levy M, Elvin J, Ross J, Pusztai L. TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer. Journal Of Clinical Oncology 2025, 43: 1043-1043. DOI: 10.1200/jco.2025.43.16_suppl.1043.Peer-Reviewed Original ResearchClinically advanced breast cancerTumor mutational burdenAdvanced breast cancerAssociated with GAGenomic alterationsWT groupTP53 WTBreast cancerMedian tumor mutation burdenTP53 genomic alterationsTP53 mutant groupPD-L1 expressionTP53 wild typeY220C mutationHomologous recombination deficiency signatureFisher's exact testMSI-highTumor suppressor geneAfrican genetic ancestryMedian GAPD-L1CDH1 mutationsLobular carcinomaMutational burdenEndocrine resistanceA pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
Mukhtar R, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy A, Laé M, Reyal F, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, Boughey J, Goetz M, Hoskin T, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Provenzano E, Sammut S, Thomas J, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, J van ’t Veer L, Cameron D, Esserman L, Fraser Symmans W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. Npj Breast Cancer 2025, 11: 14. PMID: 39948079, PMCID: PMC11825822, DOI: 10.1038/s41523-025-00720-3.Peer-Reviewed Original ResearchResidual cancer burdenInvasive lobular carcinomaEvent-free survivalNeoadjuvant chemotherapyBreast cancerAssociated with worse event-free survivalResidual cancer burden indexInvasive lobular breast cancerCancer burdenLobular breast cancerNodal statusLobular carcinomaNAC responseT categoryPrognostic significanceStratify prognosisPatient-level dataReceptor subtypesPooled analysisMultivariate analysisPooled cohortRecursive partitioningCox modelCancer cellularityCancer
2024
Spiculated Masses
Harigopal M, Andrejeva L, Lanjewar S, Podany P. Spiculated Masses. 2024, 127-158. DOI: 10.1007/978-3-031-65711-5_5.Peer-Reviewed Original ResearchInvasive ductal carcinomaInvasive lobular carcinomaDuctal carcinoma in situLobular carcinomaDuctal carcinomaSpiculated massesTumor cellsBenign entitySclerosing adenosisCorrelation of imaging findingsDesmoplastic stromal responseDiscohesive tumor cellsCore needle biopsyPseudoangiomatous stromal hyperplasiaCarcinoma in situInvasive mammary carcinomaFalse-negative mammogramsGranular cell tumorInvasive tumor cellsDiabetic mastopathyMucinous carcinomaStromal hyperplasiaInvasive cancerPleomorphic calcificationsDesmoplastic stromaArchitectural Distortions
Butler R, Durand M, Lanjevar S, Podany P, Andrejeva L, Harigopal M. Architectural Distortions. 2024, 185-207. DOI: 10.1007/978-3-031-65711-5_7.Peer-Reviewed Original ResearchInvasive lobular carcinomaLikelihood of malignancyRadial sclerosing lesionsLobular carcinomaSclerosing lesionsTubular carcinomaArchitectural distortionBenign entityDegree of proliferative changeRadial scar/complex sclerosing lesionDuctal carcinoma in situCarcinoma in situInvasive ductal carcinomaChance of malignancyIncidental microscopic findingAbsence of enhancementPost-contrast imagesMyoepithelial cell layerEntrapped glandsField digital mammographyDiscohesive cellsSonographic correlateDuctal carcinomaInvasive carcinomaPalpable massSkin Thickening and Vascular Lesions
Andrejeva L, Lanjewar S, Woolf G, Killelea B, Brownson K, Podany P, Harigopal M. Skin Thickening and Vascular Lesions. 2024, 297-323. DOI: 10.1007/978-3-031-65711-5_11.Peer-Reviewed Original ResearchRare group of neoplasmsInflammatory breast carcinomaInvasive lobular carcinomaMalignant vascular tumorsGroup of neoplasmsIll-defined marginsLobular carcinomaBreast carcinomaBenign tumorsClinical presentationBenign lesionsVascular tumorsBreast parenchymaClinical historyWell-circumscribedSkin thickeningMalignant processVascular lesionsRare groupImaging appearanceSubcutaneous tissueContrast enhancementBreastCarcinomaTumorA Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
Pareja F, Dopeso H, Wang Y, Gazzo A, Brown D, Banerjee M, Selenica P, Bernhard J, Derakhshan F, da Silva E, Colon-Cartagena L, Basili T, Marra A, Sue J, Ye Q, Da Cruz Paula A, Yeni Yildirim S, Pei X, Safonov A, Green H, Gill K, Zhu Y, Lee M, Godrich R, Casson A, Weigelt B, Riaz N, Wen H, Brogi E, Mandelker D, Hanna M, Kunz J, Rothrock B, Chandarlapaty S, Kanan C, Oakley J, Klimstra D, Fuchs T, Reis-Filho J. A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms. Cancer Research 2024, 84: 3478-3489. PMID: 39106449, PMCID: PMC11479818, DOI: 10.1158/0008-5472.can-24-1322.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaBiallelic mutationsGenetic alterationsDiagnosing ILCGenotypic-phenotypic correlationsAI modelsBiological discoveryFusion geneCancer diagnosisCDH1Artificial intelligenceWhole-slide imagesInactivation mechanismLobular carcinomaMutationsHistological whole-slide imagesHistopathological featuresValidation cohortHistological featuresBreast neoplasmsHistological ground truthImprove cancer diagnosis
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burdenMolecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report
Samreen N, Hunt KN, Hruska CB, Rhodes DJ. Molecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report. Clinical Case Reports 2019, 7: 442-444. PMID: 30899468, PMCID: PMC6406216, DOI: 10.1002/ccr3.1945.Peer-Reviewed Original Research
2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2018, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaDisease-free survivalHistologic gradeLobular carcinomaPostmenopausal womenSystemic therapyBetter prognosisAromatase inhibitorsPrognostic powerDisease-free survival advantageEarly-stage breast cancerFavorable disease-free survivalCox proportional hazards modelAdjuvant aromatase inhibitorsBaseline clinicopathologic characteristicsDetailed clinical databaseHER2-negative diseaseRetrospective cohort studyImportant prognostic factorKaplan-Meier methodProportional hazards modelIntermediate histologic gradeDistinct disease subtypesCohort studyOverall prognosisCDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis And Treatment
Luo W, Fedda F, Lynch P, Tan D. CDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis And Treatment. Frontiers In Pharmacology 2018, 9: 1421. PMID: 30568591, PMCID: PMC6290068, DOI: 10.3389/fphar.2018.01421.Peer-Reviewed Original ResearchInternational Gastric Cancer Linkage ConsortiumHereditary diffuse gastric cancer syndromeGastric cancer syndromeGastric cancerMutation carriersGermline mutationsCancer syndromesCommon germline mutationsProphylactic total gastrectomyInvasive lobular carcinomaOptimal surveillance strategySporadic diffuse gastric cancerRecent histologic studiesFamilial gastric cancerDiffuse gastric cancerMost cancer mortalityTotal gastrectomySurgical candidatesDismal prognosisCommon malignancyHistological findingsLobular carcinomaCancer mortalityColorectal cancerColorectal adenocarcinoma
2016
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis
Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research And Treatment 2016, 157: 587-596. PMID: 27271765, DOI: 10.1007/s10549-016-3845-5.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerMedian overall survivalOverall survivalPopulation-based analysisDuctal carcinomaLobular carcinomaAnnual percent changeBreast cancerIncidence rateDe novo metastatic breast cancerEnd Results 9 registriesHormone receptor-positive tumorsNovo metastatic breast cancerMultivariable Cox regression modelsStage IV breast cancerAnnual age-adjusted incidence ratesAge-adjusted incidence ratesAdjusted hazard ratioBetter overall survivalDate of diagnosisReceptor-positive tumorsBreast cancer incidenceCox regression modelHazard ratioTumor histology
2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal Of Clinical Oncology 2015, 33: 2772-2779. PMID: 26215945, PMCID: PMC4550691, DOI: 10.1200/jco.2015.60.8133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansKi-67 AntigenLetrozoleMiddle AgedNitrilesReceptor, ErbB-2TamoxifenTreatment OutcomeTriazolesConceptsInvasive ductal carcinomaInvasive lobular carcinomaDisease-free survivalLobular carcinomaDFS eventsDuctal carcinomaLA subtypeBreast International Group (BIG) 1Early-stage invasive ductal carcinomaClassic invasive lobular carcinomaHER2-negative invasive ductal carcinomaKi-67 labeling indexLow proliferative activityMagnitude of benefitAdjuvant letrozoleMedian followBIG 1ILC subsetsMultivariable modelCox modelGroup 1LetrozoleCarcinomaLabeling indexPatientsSurgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast
Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals Of Surgical Oncology 2015, 22: 4280-4286. PMID: 25893416, PMCID: PMC4801503, DOI: 10.1245/s10434-015-4570-8.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast-conserving surgeryInitial breast-conserving surgeryLocoregional recurrenceMargin statusLobular carcinomaBreast tumor recurrenceRetrospective cohort studyPositive surgical marginsInvasive lobular carcinomaMedian followInitial surgeryMultimodality therapyCohort studyFurther surgeryAdditional surgeryClinicopathologic dataSurgical marginsSurgical optionsNegative marginsTumor sizeCancer CenterClose marginsConsensus guidelinesTumor recurrence
2014
Management of Positive Sub‐areolar/Nipple Duct Margins in Nipple‐Sparing Mastectomies
Camp M, Coopey S, Tang R, Colwell A, Specht M, Greenup R, Gadd M, Brachtel E, Austen W, Smith B. Management of Positive Sub‐areolar/Nipple Duct Margins in Nipple‐Sparing Mastectomies. The Breast Journal 2014, 20: 402-407. PMID: 24890641, DOI: 10.1111/tbj.12279.Peer-Reviewed Original ResearchConceptsNipple-sparing mastectomyNipple-areola complexPositive marginsNAC specimensCancer-bearing breastsResidual invasive cancerRetrospective chart reviewInvasive lobular carcinomaResidual DCISChart reviewResidual malignancyDuctal carcinomaInvasive cancerLobular carcinomaProphylactic mastectomyDuctal tissueAreola complexTreatment informationMastectomyCarcinomaTissue removalNippleFuture studiesDCISMalignancy
2013
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.
Metzger Filho O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thurlimann B, Gelber R, Regan M, Colleoni M, Ejlertsen B, Bonnefoi H, Forbes J, Neven P, Wardley A, Lang I, Smith I, Price K, Coates A, Goldhirsch A. Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. Journal Of Clinical Oncology 2013, 31: 529-529. DOI: 10.1200/jco.2013.31.15_suppl.529.Peer-Reviewed Original ResearchMagnitude of benefitMonotherapy armYears of tamoxifenPost-menopausal womenInvasive lobular carcinomaILC patientsBetter DFSBIG 1Early BCClinicopathological variablesHistological subtypesLobular carcinomaILC subsetsPatientsTreatment assignmentDFSSignificant predictorsTamoxifenHistologyIDCGreater magnitudeClassic ILCOSArmPrevious dataClinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal Of Cancer 2013, 108: 285-291. PMID: 23299541, PMCID: PMC3566807, DOI: 10.1038/bjc.2012.557.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaBreast-conserving surgeryNeoadjuvant chemotherapyPure lobular carcinomaLobular carcinomaClinical benefitTumor sizeER-positive invasive ductal carcinomasLower pathological complete response rateResponse ratePathological complete response ratePathological response rateComplete response rateGood clinical responsePathological complete responseType of chemotherapyPositive surgical marginsSurgical resection marginsClinical responseNodal statusComplete responseResection marginsSurgical marginsDuctal carcinomaPositive margins
2012
Survival outcomes in HER2-positive invasive lobular breast carcinoma.
Barcenas C, Hess K, Delpech Y, Pusztai L, Hortobagyi G, Giordano S, Esteva F. Survival outcomes in HER2-positive invasive lobular breast carcinoma. Journal Of Clinical Oncology 2012, 30: 612-612. DOI: 10.1200/jco.2012.30.15_suppl.612.Peer-Reviewed Original ResearchInvasive lobular breast carcinomaDisease-free survivalER/PRInvasive ductal carcinomaLobular breast carcinomaSurvival outcomesOverall survivalBreast carcinomaCox proportional hazards regressionMD Anderson Cancer CenterProgesterone receptor statusRare clinical entityBreast cancer patientsProportional hazards regressionNumber of patientsAnderson Cancer CenterMedian followBetter OSMedian ageReceptor statusClinical entityDuctal carcinomaHazards regressionCancer CenterLobular carcinoma
2010
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers
Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez‐Angulo A, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers. Cancer 2010, 116: 5161-5167. PMID: 20665886, DOI: 10.1002/cncr.25269.Peer-Reviewed Original ResearchConceptsTrial Assigning Individualized OptionsRisk of recurrenceOncotype DXRecurrence scoreBreast cancerIntermediate riskGrade I/II tumorsLymph node-negative breast cancerNode-negative breast cancerStage I/IID. Anderson Cancer CenterOncotype DX breast cancerRisk estimatesIntermediate-risk populationEarly breast cancerRoutine clinical variablesHigh-risk groupOncotype DX testingAnderson Cancer CenterAdjuvant chemotherapyDistant recurrenceConsecutive patientsII tumorsClinicopathological variablesLobular carcinoma
2008
Scientific Impact Recognition Award: Molecular breast imaging: A review of the Mayo Clinic experience
Hruska CB, Boughey JC, Phillips SW, Rhodes DJ, Wahner-Roedler DL, Whaley DH, Degnim AC, O'Connor MK. Scientific Impact Recognition Award: Molecular breast imaging: A review of the Mayo Clinic experience. The American Journal Of Surgery 2008, 196: 470-476. PMID: 18723155, PMCID: PMC2603338, DOI: 10.1016/j.amjsurg.2008.06.005.Peer-Reviewed Original ResearchConceptsMolecular breast imagingInvasive ductal carcinomaInvasive lobular carcinomaDuctal carcinomaLobular carcinomaHigh-risk patientsExtent of diseaseMayo Clinic experienceBreast cancer screeningSurgical treatment planningBreast imagingMultifocal diseaseCancer screeningInstitutional protocolAdditional diseaseClinic experienceCarcinomaDiseaseFunctional uptakeTreatment planningMBI studiesPromising roleTumorsBreastCancer detection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply